Friday, May 22, 2026
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Data Updates To Be Presented In June 2026. Eledon has announced that additional data will be presented at the American Transplant Congress on June 22, 2026. The presentations will include long-term data from patients in the Phase 2 BESTOW trial and its extension study. We expect to see longer follow-up periods from additional patients than previously seen, showing outcomes, side-effect profiles, and organ survival in comparison with the standard of care, tacrolimus.
Conference Call Has Been Scheduled To Discuss Data. Eledon will hold a conference call at 8 AM on June 22 to discuss the data. This will be after the Saturday, June 20, poster presentation titled,” Phase 2 BESTOW Extension Trial Evaluating Tegoprubart’s Long-Term Safety and Efficacy in Preventing Kidney Transplant Rejection”, and before the Monday, June 22, oral presentation titled “Phase 2 BESTOW Trial: Evaluating Tegoprubart’s Safety and Efficacy in Preventing Kidney Transplant Rejection” at 12 PM.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.